BridgeBio Oncology Therapeutics is based in Palo Alto, California. It has raised $200M in total funding. Latest round: Growth.
BridgeBio Oncology Therapeutics funding overview
BridgeBio Oncology Therapeutics is based in Palo Alto, California. BridgeBio Oncology Therapeutics has raised $200M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Growth announced in May 2024. The round record for BridgeBio Oncology Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include Cormorant Asset Management, Omega Funds, Deerfield Management, GV (Google Ventures), EcoR1 Capital, Wellington Management and 5 others. 11 distinct backers are named across the disclosed rounds.
Frequently asked about BridgeBio Oncology Therapeutics funding
How much has BridgeBio Oncology Therapeutics raised?
BridgeBio Oncology Therapeutics has raised $200M in total disclosed funding across the rounds on record.
Who has invested in BridgeBio Oncology Therapeutics?
Cormorant Asset Management, Omega Funds, Deerfield Management, GV (Google Ventures), EcoR1 Capital, Wellington Management are named among the investors backing BridgeBio Oncology Therapeutics.
What was the latest BridgeBio Oncology Therapeutics funding round?
The most recent disclosed round is a Growth, announced in May 2024.
Where is BridgeBio Oncology Therapeutics based?
BridgeBio Oncology Therapeutics is based in Palo Alto, California.
When did BridgeBio Oncology Therapeutics last raise?
The last disclosed BridgeBio Oncology Therapeutics round closed in May 2024 at Growth.
Totals shown for BridgeBio Oncology Therapeutics aggregate every disclosed round on file. To see how that compares, browse the companies in Palo Alto and the investors behind them below.
Companies related to BridgeBio Oncology Therapeutics (36)
